400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Announces First Quarter 2026 Results and Provides Business Update
Annual Report to Security Holders
Financial Results, Press Release
Other Events
Investor Presentation
Retention Compensation Approved for Executive Officers at Tvardi Therapeutics
Q1
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Post-Effective Amendment
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement